Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 42
- +42 vs. Q3 2021
- Shares held
- 19.0M
- +19.0M vs. Q3 2021
- Total value
- $303.1M
- +$303.1M vs. Q3 2021
- New holders
- 42
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ameritas Investment Partners, Inc. | 573 | $9.00K | 0.00% | +573 | New |
| Legal & General Group Plc | 698 | $11.0K | 0.00% | +698 | New |
| Tower Research Capital LLC (TRC) | 961 | $15.0K | 0.00% | +961 | New |
| Morgan Stanley | 1,038 | $17.0K | 0.00% | +1,038 | New |
| Royal Bank of Canada | 1,585 | $25.0K | 0.00% | +1,585 | New |
| STRS Ohio | 1,700 | $27.0K | 0.00% | +1,700 | New |
| Citigroup Inc | 2,194 | $35.0K | 0.00% | +2,194 | New |
| American International Group, Inc. | 3,944 | $63.0K | 0.00% | +3,944 | New |
| UBS Group AG | 3,977 | $64.0K | 0.00% | +3,977 | New |
| California State Teachers Retirement System | 4,078 | $65.0K | 0.00% | +4,078 | New |
| Wells Fargo & Company | 4,462 | $71.0K | 0.00% | +4,462 | New |
| Deutsche Bank AG | 4,508 | $72.0K | 0.00% | +4,508 | New |
| Bank of America Corp | 4,774 | $76.0K | 0.00% | +4,774 | New |
| New York State Common Retirement Fund | 5,568 | $89.0K | 0.00% | +5,568 | New |
| Granite Point Capital Management, L.P. | 10,000 | $160.0K | 0.06% | +10,000 | New |
| Nuveen Asset Management, LLC | 11,284 | $181.0K | 0.00% | +11,284 | New |
| JPMorgan Chase & Co | 11,686 | $187.0K | 0.00% | +11,686 | New |
| Bank of New York Mellon Corp | 14,238 | $228.0K | 0.00% | +14,238 | New |
| Charles Schwab Investment Management Inc | 16,100 | $258.0K | 0.00% | +16,100 | New |
| Marshall Wace, LLP | 20,189 | $324.0K | 0.00% | +20,189 | New |
| Davidson Kempner Capital Management LP | 29,000 | $458.0K | 0.01% | +29,000 | New |
| Ghisallo Capital Management LLC | 30,000 | $480.0K | 0.02% | +30,000 | New |
| Caas Capital Management LP | 37,019 | $592.0K | 0.05% | +37,019 | New |
| State Street Corp | 59,210 | $947.0K | 0.00% | +59,210 | New |
| Northern Trust Corp | 63,034 | $1.01M | 0.00% | +63,034 | New |
| Geode Capital Management, LLC | 134,185 | $2.15M | 0.00% | +134,185 | New |
| Monashee Investment Management LLC | 214,253 | $3.43M | 0.85% | +214,253 | New |
| FIL Ltd | 218,705 | $3.50M | 0.00% | +218,705 | New |
| BlackRock Inc. | 324,094 | $5.18M | 0.00% | +324,094 | New |
| Norges Bank | 400,000 | $6.40M | 0.00% | +400,000 | New |
| Harvard Management Co Inc | 416,059 | $6.66M | 0.62% | +416,059 | New |
| Vanguard Group Inc | 424,224 | $6.79M | 0.00% | +424,224 | New |
| Artal Group S.A. | 450,000 | $7.20M | 0.21% | +450,000 | New |
| Soleus Capital Management, L.P. | 477,495 | $7.64M | 1.03% | +477,495 | New |
| AJU IB Investment Co., Ltd. | 667,742 | $10.7M | 14.88% | +667,742 | New |
| Rock Springs Capital Management LP | 1,191,094 | $19.1M | 0.44% | +1,191,094 | New |
| RiverVest Venture Management LLC | 1,441,444 | $23.1M | 16.45% | +1,441,444 | New |
| Ra Capital Management, L.P. | 2,002,217 | $32.0M | 0.56% | +2,002,217 | New |
| Deerfield Management Company, L.P. (Series C) | 2,154,061 | $33.7M | 0.71% | +2,154,061 | New |
| FMR LLC | 2,570,270 | $41.1M | 0.00% | +2,570,270 | New |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $44.1M | 4.06% | +2,759,344 | New |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $44.9M | 3.56% | +2,805,413 | New |